Frequently Asked Questions
U.S. and Canada dominates the market in North America due to increase in the prevalence of chronic diseases such as cancer, cardiac, and renal associated diseases.
The growth rate of the North America human leukocyte antigens (hlas) typing transplant diagnostics services market is 8.75% by 2030.
The growing burden of infectious diseases, rising public-private funding for target research activities and rising number of solid organ and stem cell transplantation procedures are the growth drivers of the North America human leukocyte antigens (hlas) typing transplant diagnostics services market.
Product and services, application, end-user, organ type, and technology are the factors on which the North America human leukocyte antigens (hlas) typing transplant diagnostics services market research is based.
Major companies in the human leukocyte antigens (HLAs) typing transplant diagnostics services market report are Johnson & Johnson Private Limited, Siemens, BD., Thermo Fischer Scientific., QIAGEN, ProImmune Ltd., Creative Biolabs., HistoGenetics LLC, UCLA Health, Quick Biology Inc., TBG Diagnostics Limited., Fujirebio, Medtronic, Omixon Inc., Takara Bio Inc., Biofortuna Limited, Luminex Corporation., Hologic, Inc., F. Hoffmann-La Roche Ltd., and Bio-Rad Laboratories, Inc.
